Evgen Pharma Share Discussion Threads

[pdt] 04/12/2018 10:03

Dave444 - SAH trial is expected to read out around year end. An interview linked to on their website with Vadim of Northlands, recorded in September 2018, suggested that it could read out this month.

Timbo - I have been eating lightly cooked brocolli for the same reason. Interestingly I have noticed an improvement in my joints, probably not related but who knows.

[dave444] 04/12/2018 08:50

When is the SAH trial due?

[timbo003] 04/12/2018 08:08

>>>>Blakeysangel

Good luck on your recovery, I do hope there is an option offered to you to continue with the tablets ad infinitum.

I find the data on sulforaphane absolutely compelling (especially the possibility of long term prophylaxis), so much so, I have been growing my own broccoli sprouts. They don't taste that brilliant and it is a bit of chore every day, but on balance I think it has got to be worth it.

[nobbygnome] 04/12/2018 07:56

But the SAH trial should be earlier so still the potential for good news shortly.

[nobbygnome] 03/12/2018 22:24

No, I am afraid I have no idea what you mean.....

[l0ngterm] 03/12/2018 22:21

Yes, and this is forum is for investors, with a risk and reward. So not the forum, you 100% know what I mean Nobby.

[nobbygnome] 03/12/2018 22:17

This an open label study so the results are not confidential. Everyone knows they are getting the drug!

[l0ngterm] 03/12/2018 22:17

Conversation

[l0ngterm] 03/12/2018 22:12

I don't care this is not the forum for this conversion.

[nobbygnome] 03/12/2018 22:04

Yes. I guess it's not really a true open label extension because the trial itself was open label!

[l0ngterm] 03/12/2018 22:02

I truly hope this is not what I expect. So please stop now.

[nobbygnome] 03/12/2018 21:35

So I presume you are eligible to enter the OLE? If so, I hope the drug maintains it's positive effect!

[nobbygnome] 03/12/2018 21:20

Excellent news!!

[l0ngterm] 03/12/2018 13:09

I would expect Bayer to show some significant interest if phase II is successful, maybe partner/buyout.

[pdt] 03/12/2018 12:13

Interesting article re Sulforaphane and Stroke



The market size for SFX-01 for use in SAH is estimated at £1 billion. SAH represents about 5% of all strokes. If the Kings pre-clinical work confirms it may be relevant to the rest of the stroke population and follow up with a clinical trial early in 2019, as they suggested, what size the whole market for SFX-01 in this area?

The Phase II results in SAH could be a real game changer.

[l0ngterm] 03/12/2018 11:27

Well hopefully we shall have further updates on the trials and progress, on the 12th of December. GLA.

[pdt] 28/11/2018 12:14

I wonder if we will get the Interims next week, usually out early December?

And the last patient in on the breast cancer trial must be having the 18 week scan around now (enrolled end of July 2018). If there is no progression the trial could go on to mid-Jan 2019 for the final 24 week scan or if there is progression (and the other patients have completed) I guess we could get trial results in December. If that is the case they may delay the Interims to announce on the same date.

I notice there is a podcast from vox markets listed on Evgen's website interviewing Vadim from Northlands in September and he repeats the expectation of a readout on the SAH trial potentially in December.



It does feel like waiting for a Bus and then all of a sudden 4 turn up at once!

[pdt] 23/11/2018 12:07

The appointment of the Corporate Finance non-exec, the interesting mortality numbers in SAH and the potential for 5 pieces of market moving news over the next 3 months (preclinical Autism, Stroke and TNBC as well as the two phase IIs) persuaded me to have a small top up today :)

[nico115] 23/11/2018 08:22

Why would anyone sell when we ran up 150 pct last time pre trial results Any sellers will be looking to offload in the mid 20s not here I'm expecting 25p next month

[nobbygnome] 23/11/2018 08:10

No amount of shares being offered on line this morning......which is frustrating!

[l0ngterm] 21/11/2018 12:29

As the company is that close to the finishing the trials, I would expect an RNS for any trial completions etc. So I doubt much more was shared last night, unless there were any early stage updates in other areas.

[nico115] 21/11/2018 07:53

Any feedback from the Mello presentation please ?

[pdt] 20/11/2018 13:39

L0ngterm, I have seen that before but had not grasped the significance of the mortality number so thanks for highlighting.

I think the mortality rate is normally something like 40% in the first couple of weeks so the drug arm of the trial must be considerably lower than normal if they are reporting 9.5% across the whole trial.

This is possibly due to improved blood flow which will be confirmed by the TCD endpoint results in due course.

Very interesting.